Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKYLINE: AGTC-501 in X-linked Retinitis Pigmentosa
NCT06333249Phase 2Active, not recruiting
- Sponsor
- Beacon Therapeutics
- Start
- Apr 2021
- Primary completion
- Apr 2023
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of laruparetigene zovaparvovec in X-linked retinitis pigmentosa (XLRP), sponsored by Beacon Therapeutics. Started Apr 2021; status: active, not recruiting.
02
Drugs
laruparetigene zovaparvovec
03
Conditions
X-linked retinitis pigmentosa (XLRP)
Beyond the preview
Go deeper on NCT06333249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06333249.